Trinity Biotech Plc (TRIB)
NASDAQ:TRIB
Want to see TRIB full AI Analyst Report?
TRIB Stock Chart & Stats
$0.75
-$0.09(-10.05%)
At close: 4:00 PM EST
$0.75
-$0.09(-10.05%)
Day’s Range― - ―
52-Week Range$0.50 - $3.44
Previous CloseN/A
Volume141.89K
Average Volume (3M)136.14K
Market Cap
$13.55M
Enterprise Value$140.15M
Total Cash (Recent Filing)$5.14M
Total Debt (Recent Filing)$137.98M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding20,250,870
10 Day Avg. Volume159,092
30 Day Avg. Volume136,139
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.20
Price to Sales (P/S)0.33
P/FCF Ratio-2.32
Enterprise Value/Market Cap10.34
Enterprise Value/Revenue3.20
Enterprise Value/Gross Profit9.02
Enterprise Value/Ebitda-16.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$59.50M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelTrinity’s core IVD model couples instrument placements with repeat consumable sales (reagents/test kits), creating predictable recurring revenue tied to testing volumes. Over 2–6 months this supports revenue durability, installed‑base leverage and resilience versus one‑time product sales.
Operational & Margin ImprovementManagement reports scaled outsourced HIV production, rising gross margins and much smaller adjusted EBITDA losses. If sustained, outsourcing and cost discipline can convert a structurally mid‑30% gross margin into positive operating leverage, improving cash generation potential over the medium term.
Advancing CGM And PipelineMaterial CGM+ technical advances and a move toward a 2026 pivotal trial position Trinity to enter a high‑growth CGM market with an AI‑native, multimodal product. Successful commercialization would diversify revenue away from legacy HIV/hemoglobin lines and create a durable, differentiated growth avenue.
Bears Say
Highly Stressed Balance SheetNegative shareholder equity and rising debt materially weaken financial flexibility and increase refinancing risk. Over the next few months, a fragile capital structure limits ability to fund commercialization or absorb shocks, raising solvency concerns if operational improvements slip.
Negative Operating Cash FlowSustained negative operating and free cash flow means the business consumes cash rather than self‑funding growth. Even with narrower FCF losses in 2025, ongoing cash burn forces dependence on external financing or covenant relief, constraining strategic execution and increasing dilution or creditor risk.
Revenue Decline & Sustained LossesA steep revenue decline reduces scale needed to absorb fixed costs and undermines profitability recovery. Despite mid‑30% gross margins, shrinking top line has produced multi‑year net losses, meaning operational gains must be sizable and sustained to restore break‑even and rebuild stakeholder confidence.
Trinity Biotech News
TRIB FAQ
What was Trinity Biotech Plc’s price range in the past 12 months?
Trinity Biotech Plc lowest stock price was $0.50 and its highest was $3.44 in the past 12 months.
What is Trinity Biotech Plc’s market cap?
Trinity Biotech Plc’s market cap is $13.55M.
When is Trinity Biotech Plc’s upcoming earnings report date?
Trinity Biotech Plc’s upcoming earnings report date is Sep 03, 2026 which is in 90 days.
How were Trinity Biotech Plc’s earnings last quarter?
Currently, no data Available
Is Trinity Biotech Plc overvalued?
According to Wall Street analysts Trinity Biotech Plc’s price is currently Overvalued.
Does Trinity Biotech Plc pay dividends?
Trinity Biotech Plc pays a Annually dividend of $1.1 which represents an annual dividend yield of N/A. See more information on Trinity Biotech Plc dividends here
What is Trinity Biotech Plc’s EPS estimate?
Trinity Biotech Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trinity Biotech Plc have?
Trinity Biotech Plc has 20,250,870 shares outstanding.
What happened to Trinity Biotech Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Trinity Biotech Plc?
Currently, no hedge funds are holding shares in TRIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Trinity Biotech Plc
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Technical Analysis
―
Precipio
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
0.08% Mutual Funds
4.63% Other Institutional Investors
95.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---